Karyopharm Therapeutics | KPTI - Trade Creditors


Karyopharm Therapeutics reported $4.28M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Abbott USD 4.68B 439M Mar/2026
Amgen USD 2.86B 16.65B Jun/2026
AstraZeneca USD 22.89B 388M Jun/2026
BioCryst Pharmaceuticals USD 11.46M 501K Jun/2026
Bristol-Myers Squibb USD 4.16B 76M Jun/2026
Eli Lilly USD 6.11B 1.08B Jun/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
GlaxoSmithKline GBP 14.34B 7M Jun/2026
Incyte USD 1.39B 1.16B Jun/2026
J&J USD 9.22B 1.24B Jun/2026
Karyopharm Therapeutics USD 4.28M 276K Mar/2026
MacroGenics USD 3.44M 845K Jun/2026
Merck USD 3.83B 36M Jun/2026
Nektar Therapeutics USD 10.03M 744K Mar/2026
Novartis USD 4.26B 64M Jun/2026
Novartis USD 4.32B 134M Mar/2026
Pfizer USD 4.58B 75M Jun/2026
Regeneron Pharmaceuticals USD 1.16B 132.2M Jun/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Takeda JPY 446.78B 44.56B Jun/2026
Tectonic Therapeutic USD 2.55M 1.46M Mar/2026
TG Therapeutics USD 213.69M 64.85M Jun/2026
Ultragenyx Pharmaceutical USD 39M 3M Jun/2026
Xencor USD 12.65M 4.73M Jun/2026